Logo image of ALXN

Alexion Pharm Inc (ALXN) Stock Fundamental Analysis

USA - NASDAQ:ALXN -

182.5
+3.05 (+1.7%)
Last: 7/20/2021, 9:56:13 PM
183
+0.5 (+0.27%)
After Hours: 7/20/2021, 9:56:13 PM
Fundamental Rating

3

ALXN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. The financial health of ALXN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ALXN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ALXN had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 9.15%
PM (TTM) 10.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

ALXN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 5.06 indicates that ALXN is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.19 indicates that ALXN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 5.06
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ALXN has a Current Ratio of 4.52. This indicates that ALXN is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.96 indicates that ALXN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 3.96

5

3. Growth

3.1 Past

ALXN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.94%, which is quite good.
ALXN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.12% yearly.
Looking at the last year, ALXN shows a quite strong growth in Revenue. The Revenue has grown by 18.24% in the last year.
ALXN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.44% yearly.
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%

3.2 Future

The Earnings Per Share is expected to grow by 6.32% on average over the next years.
The Revenue is expected to grow by 7.94% on average over the next years.
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALXN Yearly Revenue VS EstimatesALXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
ALXN Yearly EPS VS EstimatesALXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.22, which indicates a correct valuation of ALXN.
The average S&P500 Price/Earnings ratio is at 27.41. ALXN is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 12.48, which indicates a correct valuation of ALXN.
When comparing the Price/Forward Earnings ratio of ALXN to the average of the S&P500 Index (22.87), we can say ALXN is valued slightly cheaper.
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
ALXN Price Earnings VS Forward Price EarningsALXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.39
ALXN Per share dataALXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

ALXN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.44
PEG (5Y)0.71
EPS Next 2Y8.02%
EPS Next 3Y8.65%

0

5. Dividend

5.1 Amount

No dividends for ALXN!.
Industry RankSector Rank
Dividend Yield N/A

Alexion Pharm Inc

NASDAQ:ALXN (7/20/2021, 9:56:13 PM)

After market: 183 +0.5 (+0.27%)

182.5

+3.05 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)02-22 2022-02-22/bmo
Inst Owners0%
Inst Owner Change-97.22%
Ins Owners0.8%
Ins Owner Change0%
Market Cap40.34B
Analysts66.2
Price Target180.9 (-0.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB N/A
EV/EBITDA 13.39
EPS(TTM)12.83
EY7.03%
EPS(NY)14.62
Fwd EY8.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS28.33
BVpS56.24
TBVpSN/A
PEG (NY)1.44
PEG (5Y)0.71
Profitability
Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.15%
PM (TTM) 10.89%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 3.96
Altman-Z 5.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A